Literature DB >> 18571387

Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation.

José Barberán1, Lorenzo Aguilar, María-José Giménez, Guillermo Carroquino, Juan-Jose Granizo, José Prieto.   

Abstract

Therapeutic conclusions for staphylococcal implant infections treated with debridement and implant retention can only be drawn from a small series. To this aim, data from patients with implant staphylococcal infections (1998-2006) treated with debridement and implant retention were retrospectively reviewed. Infections were defined by staphylococci isolation (two or more consecutive debridement or three sinus tract discharge samples) along with clinical criteria. Patients received oral levofloxacin plus rifampicin for >or=6 weeks after the resolution of signs/symptoms and C-reactive protein normalisation. Failure was defined as lack of response or recurrence of signs/symptoms and/or sinus tract bacterial isolation during therapy or follow-up and/or implant removal. Twenty-five patients (53.2+/-20.8 years; 48% males) were included, 12 with spinal infections and 13 with limb implant infections. Diagnosis was performed from debridement material (72%) and sinus tract discharge (28%) (11 Staphylococcus aureus and 14 coagulase-negative staphylococci (CoNS)). Time from surgery to symptom onset was higher in CoNS infections compared with S. aureus infections (21.6+/-9.3 days vs. 12.6+/-5.2 days; P=0.007). Seven patients (28%) were failures, with no differences between cured patients with respect to age, sex, infection site, time from surgery to symptom onset, sinus tract diagnosis and aetiology. Longer symptom duration prior to attendance was observed in failures (5.7+/-6.2 months vs. 1.4+/-0.6 months; P=0.04). Levofloxacin plus rifampicin showed efficacy in implant infections, which was higher for short duration of symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571387     DOI: 10.1016/j.ijantimicag.2008.03.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Remission rate of implant-related infections following revision surgery after fractures.

Authors:  Mohamed Al-Mayahi; Michael Betz; Daniel A Müller; Richard Stern; Phedon Tahintzi; Louis Bernard; Pierre Hoffmeyer; Domizio Suvà; Ilker Uçkay
Journal:  Int Orthop       Date:  2013-09-20       Impact factor: 3.075

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

4.  Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.

Authors:  Rafael San Juan; Ana Garcia-Reyne; Pedro Caba; Fernando Chaves; Carlos Resines; Fernando Llanos; Francisco López-Medrano; Manuel Lizasoain; Jose Maria Aguado
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

5.  Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study.

Authors:  Y Achermann; K Eigenmann; B Ledergerber; L Derksen; P Rafeiner; M Clauss; R Nüesch; C Zellweger; M Vogt; W Zimmerli
Journal:  Infection       Date:  2012-09-19       Impact factor: 3.553

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.

Authors:  Milagrosa Montes; Esther Tamayo; Beatriz Orden; Julián Larruskain; Emilio Perez-Trallero
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

8.  Effect of a standardized treatment regime for infection after osteosynthesis.

Authors:  Pien Hellebrekers; Luke P H Leenen; Meriam Hoekstra; Falco Hietbrink
Journal:  J Orthop Surg Res       Date:  2017-03-09       Impact factor: 2.359

9.  The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.

Authors:  Peter Ankomah; Paul J T Johnson; Bruce R Levin
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.